Form 4 for TRDA Entrada Therapeutics, Inc.
Accepted 2025-03-04 00:00:00 ET · period of report 2025-03-01 · accession 0001689375-25-000015 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-04 | 2025-03-03 | TRDA | Doshi Dipal | CEO, Dir | F - Tax | $11.68 | -17.6K | 424.4K | -4% | -$205.2K |
| D | 2025-03-04 | 2025-03-01 | TRDA | Doshi Dipal | CEO, Dir | A - Grant | $0.00 | +116.2K | 442.0K | +36% | $0 |
| D | 2025-03-04 | 2025-03-01 | TRDA | Doshi Dipal | CEO, Dir | A - Grant | $0.00 | +173.4K | 173.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-03 | F | D | 17,566 | $11.68 | 424,387 | D | — | — | (F2) This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.30 to $11.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2025-03-01 | A | A | 116,200 | $0.00 | 441,953 | D | — | — | (F1) Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2026; (ii) 25% on March 1, 2027; (iii) 25% on March 1, 2028 and (iv) the remaining 25% on March 1, 2029, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-03-01 | A | A | 173,400 | $0.00 | 173,400 | D | $11.94 · — to 2035-03-01 | 173,400 Common Stock | (F4) 25% of the option shares shall vest and become exercisable on March 1, 2026, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2029. |